Profil
Lisa M.
Bell worked as a Senior Director-Regulatory & Safety at Abbott Biotherapeutics Corp.
and as the Head-Regulatory & Pharmacovigilance at BioMarin Pharmaceutical, Inc. She was also the Senior Vice President- Global Regulatory Affairs at Coherus BioSciences, Inc. from 2014 to 2017.
Bell received her undergraduate and graduate degrees from Boston University and her doctorate from the University of California, Berkeley.
Tidigare kända positioner av Lisa M. Bell
| Företag | Position | Slut |
|---|---|---|
| COHERUS ONCOLOGY, INC. | Generell Rådgivare | 2017-12-01 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for the treatment of oncology and immunologic diseases | Generell Rådgivare | - |
| BIOMARIN PHARMACEUTICAL INC. | Generell Rådgivare | - |
Lisa M. Bells utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for the treatment of oncology and immunologic diseases | Health Technology |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coherus BioSciences, Inc.
Coherus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial-stage biopharmaceutical company that engages in research, development and commercialization of immunotherapies to treat cancer | Health Technology |
















